Item 9.01 Financial Statements and Exhibits.
(a) Financial Statements of Businesses Acquired.
1. The financial statements of
the fiscal year endedDecember 31, 2018 , together with the notes thereto and the report of independent registered public accounting firm thereon, are filed as Exhibit 99.1 to this Amendment No. 1 to Current Report on Form 8-K/A and are incorporated herein by reference.
2. The unaudited financial statements of
of and for the nine months endedSeptember 30, 2019 , together with the notes thereto, are filed as Exhibit 99.2 to this Amendment No. 1 to Current Report on Form 8-K/A and are incorporated herein by reference.
(b) Pro Forma Financial Information.
1. Unaudited pro forma condensed combined balance sheet as ofSeptember 30, 2019 and unaudited statements of operations for the year endedSeptember 30, 2019 , each giving effect to the Acquisition and related financing, and the notes thereto, are filed as Exhibit 99.3 to this Amendment No. 1 to Current Report on Form 8-K/A and are incorporated herein by reference. They were prepared for informational and illustrative purposes in accordance with Rule 8-05 of Regulation S-X. Such information is preliminary and based on currently available information and assumptions that the Company believes are reasonable but may be subject to change. They shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as set forth by specific reference in such filing. (c) None.
(d) Exhibits
The following exhibits are being filed as part of this report:
Exhibit No. Description 23.1 Consent ofSoukup, Bush & Associates P.C. , independent registered public accounting firm toPre-Clinical Research Services, Inc. 99.1 Audited financial statements of Pre-Clinical Research Services, Inc. as of and for the fiscal year endedDecember 31, 2018 , together with the notes thereto and the report of independent registered public accounting firm thereon. 99.2 Reviewed financial statements of Pre-Clinical Research Services, Inc. as of and for the nine months endedSeptember 30, 2019 , together with the notes thereto and the report of independent registered public accounting firm thereon. 99.3 Unaudited pro forma condensed consolidated balance sheet as ofSeptember 30, 2019 and unaudited condensed consolidated statements of operations and comprehensive income (loss) for the year endedSeptember 30, 2019 , each giving effect to the acquisition ofPre-Clinical Research Services, Inc. and related financing, and the notes thereto.
© Edgar Online, source